The Effect of Micro-doses Erytropoietin on Exercise Capacity in Male and Females

Sports Drug Abuse Clinical Trial

Official title: Plasma and Exosome Proteomic Changes Associated With Augmented Erythropoiesis and Muscle Contractions.

Status Active, not recruiting

Clinical Trial Summary

Recombinant human erythropoietin (rHuEPO) regimen enhances maximal oxygen consumption (VO2max), but the effect of micro-doses on maximal and submaximal performance is not clear and detection of micro-doses is difficult with current methods. This study investigated whether micro-doses of rHuEPO enhances maximal and endurance performance in males and females.

Clinical Trial Description

In a randomized, double-blind, placebo-controlled design, 48 trained adults (24 females, 24 males) receive either recombinant human erythropoietin (rHuEPO; epoetin-β, 9 IU/kg, n = 24, (12 females, 12 males)) or placebo (0,9% NaCl, n = 24, (12 females, 12 males)) three times per week for four weeks. Before the intervention, time trial performance and maximal oxygen uptake will be assessed. Three and five days after the last injection, time trial performance and maximal oxygen uptake will be determined to assess the effect of the rHuEPO administration. In addition, total hemoglobin mass and intravascular volumes will be determined via the carbon monoxide rebreathing method in duplicate measures. ;

Related Conditions & MeSH terms

• Sports Drug Abuse
• Substance-Related Disorders

• NCT number: NCT04965961
• Study type: Interventional
• Source: University of Copenhagen
• Status: Active, not recruiting
• Phase: N/A
• Start date: August 28, 2019
• Completion date: January 2024